Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating
Published . Updated .
Fintel reports that on September 30, 2026, Canaccord Genuity initiated coverage of First Tracks Biotherapeutics (NASDAQGS:TRAX) (BMV:TRAX) with a Buy recommendation.Prior to this rating action, the stock recorded a pre_action_close of $35.98 on September 29, 2026, which is also t
Directly affected
- TRAX First Tracks Biotherapeutics
Named in this report.
Indirectly affected
- UPGD INVESCO BLOOMBERG ANALYST RATING ETF
GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on September 30, 2026, Canaccord Genuity initiated coverage of First Tracks Biotherapeutics (NASDAQGS:TRAX) (BMV:TRAX) with a Buy recommendation.Prior to this rating action, the stock recorded a pre_action_close of $35.…
Source: Nasdaq Markets
Price since this story was published: Invesco Bloomberg Analyst Rating Etf (UPGD)
Since the first closing price after “Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating,” Invesco Bloomberg Analyst Rating Etf (UPGD) is +2.30%. The S&P 500 fund (SPY) is +0.33% over the same days, a +1.97% difference versus the market.
Who gains and who loses around Invesco Bloomberg Analyst Rating Etf (UPGD)
Companies carried with this story
- UPGD Invesco Bloomberg Analyst Rating Etf
Invesco Bloomberg Analyst Rating Etf (UPGD) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating.” Reason on file: GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- TRAX First Tracks Biotherapeutics
First Tracks Biotherapeutics (TRAX) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating.” Reason on file: GA selected TRAX as a RELATED security because its canonical security name directly matches this event's themes: biotherapeutics, tracks. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Invesco Bloomberg Analyst Rating Etf (UPGD)
On 30 Sep 2026, “Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating” is the story that connects Invesco Bloomberg Analyst Rating Etf (UPGD) to this story.
Invesco Bloomberg Analyst Rating Etf (UPGD) is on the page because GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
First Tracks Biotherapeutics (TRAX) is here too. Its reason reads: GA selected TRAX as a RELATED security because its canonical security name directly matches this event's themes: biotherapeutics, tracks. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Invesco Bloomberg Analyst Rating Etf (UPGD), and the dates in the story
TRAX traded between 30.37 and 42.23 across 20 sessions. The latest close on file is 36.22. UPGD traded between 80.14 and 82.00 across 17 sessions. The latest close on file is 82.00.
How strong the case is around Invesco Bloomberg Analyst Rating Etf (UPGD)
21 out of 100
“Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating” scores 21 out of 100. The score uses 1 sources, and 2 linked companies.